Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Dilated cardiomyopathy (DCM) is the most common childhood cardiomyopathy and is associated
with significant early morbidity and mortality. About half of patients die or require heart
transplantation within 5 years of diagnosis. The medical therapy for DCM with heart failure
includes anti-congestive medications and antiplatelet therapy. Those who fail to improve
within the first year of diagnosis usually deteriorated even upon aggressive anti-congestive
medications. The investigators had conducted precision-medicine-based approach to provide
strategic approach as drug repurposing to identify new treatments. The investigators have
identified the beneficial effects from a statin, simvastatin, to restore the cardiac
contractility. The investigators would further assess the efficacy of simvastatin to improve
the cardiac function in patients with DCM.